Product
Circulating Tumor DNA
1 clinical trial
2 indications
Indication
Ovarian Serous AdenocarcinomaIndication
High-grade serous carcinomaClinical trial
Integration of Multiple Data Levels to Improve Diagnosis, Predict Treatment Response and Suggest Targets to Overcome Therapy Resistance in High-grade Serous Ovarian CancerStatus: Recruiting, Estimated PCD: 2027-12-01